Medera completes patient dosing in Phase 1/2a MUSIC-HFrEF

Medera announced that patient dosing has been completed in its MUSIC-HFrEF Phase 1/2a clinical trial of the gene therapy candidate SRD-001 in patients with heart failure with reduced ejection fraction, HErEF. “The completion of enrollment in the Phase 1/2a trial marks a crucial milestone for this cardiac gene therapy trial in patients with heart failure with reduced ejection fraction. We are encouraged that this therapy may help patients with advanced heart failure who have few therapeutic options,” said Brian Jaski, M.D., the Principal Investigator of MUSIC-HFrEF and Director of Cardiology at San Diego Cardiac Center. On September 5, 2024, Medera and Keen Vision Acquisition (KVAC) Corporation announced they had entered into a definitive merger agreement